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Abstract 
Background: Although severe malaria by Plasmodium vivax has been increasingly reported, there are marked varia‑
tions in the type and rate of the complications by geographic area. This is possibly because of the presence of concur‑
rent falciparum malaria or bacteraemia, and of differences in underlying immune status among the infected subjects. 
Furthermore, published studies on P. vivax in temperate regions are limited. The present study investigated severe 
vivax malaria in Korea, where only vivax malaria occurs. Hence, other compounding factors are rare. Additionally, most 
of the patients are possibly non‑immune to this malarial disease.
Methods: Adults with vivax malaria observed in one 860‑bed university hospital from January 2006 to December 
2012 were retrospectively evaluated. Seventeen patients who had travelled overseas within 6 months before the 
presentation of malaria were excluded. Severe vivax malaria was diagnosed according to World Health Organization 
criteria. Other complications were also investigated.
Results: Two‑hundred and ten patients were enrolled, of which 88 (41.9%) were treated as inpatients and the 
remainder as outpatients. Eleven patients were treated in an intensive care unit; among them, five patients received 
mechanical ventilation, and one needed extracorporeal membrane oxygenation therapy (ECMO) additionally. Severe 
vivax malaria was identified in 44 patients (21.0%), and the most common severe complication was pulmonary 
manifestation (40/188, 21.9%), which was followed by cerebral malaria (5/210, 2.4%), shock (4/210, 1.9%), spontaneous 
bleeding (3/210, 1.4%), metabolic acidosis (3/210, 3.5%) and acute kidney injury (2/210, 1.0%). Unusual complications, 
such as splenic infarction (ten patients) and retinal haemorrhage (two patients) were sometimes observed. There 
were no deaths, but the case involving ECMO was potentially fatal.
Conclusions: Plasmodium vivax infection can be severe to be fatal and is frequently associated with various com‑
plications in non‑immune adults. The frequency of each complication seems to differ from other countries. Hence, 
further investigation is needed to elucidate the causes and mechanisms responsible for these differences.
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Background
Malaria is a protozoan disease transmitted by Anopheles 
mosquito. The disease presents as an acute febrile illness, 
characterized by the classic malaria paroxysm, namely, 
chills and rigours, followed by fever spikes, and then pro-
fuse sweating [1]. About 120 types of Plasmodium spe-
cies have been reported, although only five are accepted 
as human malaria parasites. Notably, Plasmodium falci-
parum and Plasmodium vivax cause most of the human 
infections worldwide [2]. Vivax malaria is typically accom-
panied by relatively less severe complications than falcipa-
rum malaria. However, there have been increasing reports 
of severe vivax malaria, including respiratory distress [3, 
4], acute kidney injury [5, 6] and cerebral malaria [7, 8], 
which have been attributed to various factors [9]. These 
reports were mainly from tropical regions, while only a 
few studies have investigated malaria in temperate regions, 
such as Europe and Far-east Asia [10–12]. A recent review 
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of severe vivax complications also suggests that geographi-
cal heterogeneity may be caused by endemicity and chlo-
roquine resistance [13]. Moreover, additional differences, 
such as medical facilities, co-morbidity and co-infection, 
between South Korea and other areas, can contribute to 
dissimilarities in vivax malaria complications.
In Korea, P. falciparum infection was once present 
among intravenous drug abusers, while indigenous falci-
parum malaria has not been reported since 1945. Plasmo-
dium malariae was also present before 1945, but has not 
occurred since. In addition, the transboundary movement 
is impossible in Korea due to the geographic (peninsula) 
and political situation (North Korea). Thus, misdiagno-
sis or mixed infection with P. falciparum imported from 
abroad is not possible in South Korean residents with no 
history of overseas travel. In contrast, vivax malaria had 
been prevalent in Korea for many centuries, its incidence 
decreased rapidly from the 1970s. The Republic of Korea 
(South Korea) was declared to be a malaria-free area in 
1979 [14]. However, vivax malaria re-emerged in 1993. It 
was initially localised to the area around the border with 
North Korea but has since spread from west to east along 
the Demilitarized Zone (DMZ), although the endemic 
area has not yet extended south beyond the neighbour-
ing provinces [15–17]. As indigenous vivax malaria has 
not occurred for nearly 30 years in most areas of Korea, 
most Koreans, particularly those under 40  years of age, 
are vivax malaria-naïve. Thus, the effect of pre-existing 
specific immunity on the manifestation of malaria can 
be excluded. Furthermore, the possibility of recurrent or 
reinfection with P. vivax is also very low.
The Korean population has a relatively high socio-
economic status and appropriate medical care system. 
Consequently, other contributing factors, including sal-
monellosis, dengue fever, and nutritional deficiency, rarely 
or do not occur, which minimizes the effects of these con-
founding factors. Additionally, chloroquine resistance to P. 
vivax is rare [17, 18], so the failure of anti-malarial therapy 
is not an issue. In this context, vivax malaria in Korea is 
an ideal model to evaluate the clinical manifestations and 
complications of vivax malaria, unaffected by compound-
ing factors or pre-existing immunity against P. vivax. 
Hence, the present study investigated the type and fre-
quency of severe vivax malaria complications in Korea and 
the development of risk factors associated with the disease.
Methods
Study site and population
The present study was based at INHA university hospi-
tal (Sinheung-Dong, Jung-Gu, Incheon, South Korea) 
which has 860 beds, a 24-h emergency department and 
an intensive care unit (ICU) with facilities for mechanical 
ventilation and extracorporeal membrane oxygenation 
(ECMO). Incheon has an area of 1010 km2 and 2.7 mil-
lion people with areas endemic for malaria because it 
is close to the (DMZ) in north-western South Korea. 
Between 2006 and 2012, The Korea Centre for Disease 
Control reported 257 and 1406 malaria incidences in 
Incheon and South Korea, respectively [19]. Figure  1 
shows the malaria endemic areas in South Korea [20] and 
the location of INHA university hospital (37°45′881′′N, 
126°63′192′′E).
Both in- and outpatients with vivax malaria, who were 
diagnosed from January 2006 to December 2012 were 
included in the study. Their diagnosis was confirmed by 
peripheral blood smear examination, which was per-
formed by an expert. In order to exclude co-infection with 
other malarial species imported from abroad, patients 
who had a history of overseas travel within 6  months 
before the presentation of the current malaria were 
excluded. Children were also excluded, for the conveni-
ence of comparison with previous reports. The study was 
conducted by retrospective review of medical records, 
and demographic and radiologic data. Underlying dis-
eases and laboratory examinations were recorded. Severe 
malaria was classified according to World Health Organi-
zation (WHO) criteria for P. falciparum [21], namely 
consciousness, convulsion (more than 2 per 24 h), hypo-
tension (systolic blood pressure  <80  mmHg), bleeding 
tendency, pulmonary oedema (by chest roentgenogram 
or computed tomography (CT)), hypoxaemia (oxygen 
saturation  <92% on room air), severe anaemia (haemo-
globin  <7  g/dL together with a parasite count  >10,000/
μL), jaundice (serum total bilirubin >3 mg/dL in conjunc-
tion with a parasite count  >100,000/μL), hypoglycaemia 
(serum glucose  <40  mg/dL), metabolic acidosis (bicar-
bonate  <15  mmol/L or lactate  >5  mmol/L), and renal 
failure (creatinine  >3  mg/dL or blood urea  >60  mg/dL). 
Additionally, laboratory data were recorded on mus-
cle enzymes (creatinine phosphokinase), haematuria 
(by microscopic examination), parasitaemia (by micro-
scopic examination, asexual forms/μL,  >10%), alanine 
aminotransferase, aspartate aminotransferase, uric acid, 
prothrombin time (PT), and partial thromboplastin time 
(aPTT). For evaluations of complications other than 
severe malaria, the presence of bacteraemia [with blood 
culture using the BACTEC system (BD Diagnostic Sys-
tems, Franklin Lakes, NJ, USA)], retinal haemorrhage 
and other ophthalmologic complications (consult sheets 
to an ophthalmologist), splenic complications (with CT 
or ultrasonography) were reviewed.
Ethics statement
This study was approved by the IRB of INHA Univer-
sity Hospital, Incheon, Korea. All patients’ records were 
anonymized.
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Statistical analysis
The characteristics of the groups are represented as 
the mean and standard deviation (SD). For age, para-
sitaemia and the time taken to visit the hospital from 
the first onset of symptoms, the median and inter-
quartile range (IQR) was reported because the Shap-
iro–Wilk test showed that the outcome measures did 
not have a normal distribution. Furthermore, logistic 
regression analyses were used to understand the indi-
vidual risk factors for pulmonary oedema. The follow-
ing independent variables were measured: age, gender, 
chronic morbidity, the first onset of symptoms, para-
site counts and estimated glomerular filtration rate 
(eGFR), while there were insufficient events to evalu-
ate shock, spontaneous bleeding, metabolic acidosis 
and cerebral malaria. Haemoglobin, total bilirubin, 
platelet counts and glucose were not included in the 
analyses, as these parameters are not deemed risk fac-
tors for pulmonary oedema. For the logistic regression 
model, platelet and parasite counts were respectively 
analysed after log transformation. Only independent 
variables with P value  <0.2 were considered for the 
final logistic regression model. The Hosmer–Leme-
show test was used to check the logistic model fitting. 
Finally, multivariate analysis was performed using 
an enter method. Data analysis was performed using 
Fig. 1 The spatial distribution of Plasmodium vivax malaria in Korea and the location of INHA university hospital. Black arrow indicates the Demili‑
tarised Zone (DMZ), which is 250 km long and 4 km wide, and serves as a political and military buffer zone between South Korea and North Korea. 
Dark red and light red areas indicate the endemicity of vivax in South Korea. The green star indicates the location of INHA university hospital
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SPSS statistical software (version 18, SPSS Inc, Chi-
cago, USA).
Results
General characteristics of vivax malaria patients
Two-hundred and thirty-one patients were diagnosed 
with P. vivax infection by blood smear. Of these patients, 
17 were excluded due to a history of overseas travel 
within 6  months of presenting with the illness. Four 
patients under 15  years of age (median age of 11  years) 
were also excluded. The children were treated in the gen-
eral ward, none had a severe manifestation of the disease 
and all were discharged from the hospital uneventfully. 
Thus, a total of 210 patients with vivax malaria were 
included in the study. The study included 73.3% (154/210) 
males and 26.7% (56/210) females. The median age was 
39.0 (IQR 23.8–49.0) years. There were 122 outpatients, 
and 88 (including 11 ICU patients) inpatients. Frequent 
underlying illnesses were hypertension or diabetes mel-
litus. There were no pregnant woman or HIV-infected 
patients (Table  1). The median time taken to visit the 
hospital from the first onset of symptoms was 7.0 (IQR 
4.8–10) days. Two patients had a history of vivax malaria. 
Most patients were treated with oral chloroquine plus 
primaquine. If the patients were unable to take oral chlo-
roquine for severe vivax malaria, they received intrave-
nous anti-malarial drug.
Laboratory finding of vivax malaria patients
Leukocytosis (leukocyte count  >12,000/μL) was present 
in 0.5% of the patients and 34.3% showed leukopaenia 
(leucocyte count  <4000/μL), and 29.5% had anaemia 
(haemoglobin  <12  g/dL). The most common laboratory 
abnormality (91.4% occurrence) was thrombocytopae-
nia (<150,000/μL), whilst 4.4% (9/204) showed renal fail-
ure (creatine  >1.5  mg/dL). The levels of transaminases 
(aspartate transaminase (AST) or alanine transaminase 
(ALT)) were elevated (>  three times normal) in 10.8% 
of the patients. Coagulopathy (aPTT  >60  s or PT inter-
national normalized ratio (INR)  >1.5) occurred in 2.9% 
(5/174). Hyperuricaemia (≥10  mg/dL) showed in 1.6% 
(3/190). The median value of parasitaemia was 3152.5/μL 
(IQR 1089.8–8285.0). According to microscopic exami-
nation of the urine, 2.5% (4/162) showed macrohaemo-
globinuria (red blood cell  >20 elements per high power 
field (HPF)) (see Additional file 1).
Severe complication of vivax malaria (according to WHO 
criteria)
Among 210 patients, 44 (21.0%) had one or more severe 
complications of vivax malaria, according to the WHO 
criteria (Table 4). Pulmonary manifestations presented in 
40/183 (21.9%), and mechanical ventilation was used to 
treat respiratory failure in five patients. There were 5/210 
patients (2.4%) with cerebral malaria, while 3/210 (1.4%) 
with spontaneous bleeding with 4/210 (1.9%) with hypo-
tensive shock. Severe acute kidney injuries occurred at 
1.0% (2/204) and metabolic acidosis at 3.5% (3/86). There 
was no hypoglycaemia, severe anaemia or severe jaun-
dice (Table 2). There were no deaths, but one patient with 
multi-organ failure was potentially fatal, but successfully 
recovered after management with ECMO, continuous 
venovenous filtration (CVVH) and mechanical ventila-
tion, as previously reported [22].
Analyses of the hospitalisation and the risk factors 
for pulmonary oedema
The decision to hospitalise or admit the patients to the 
ICU was based on the clinical judgement of the attend-
ing physicians. Mechanical ventilation was considered 
when the patient had unresolved hypoxaemia with a 
supplemental fraction of inspired oxygen. Among 210 
vivax malaria patients, 77 were treated in the general 
wards and 11 in the ICU (including four cases with 
mechanical ventilation only and one case with ECMO, 
CVVH and mechanical ventilation). All ICU cases 
had pulmonary oedema (11 patients) and all patients 
with shock or cerebral malaria presented pulmonary 
oedema. Although nine severe malaria patients were 
treated as outpatients, seven had pulmonary oedema 
without hypoxaemia. Two separate cases of spontane-
ous bleeding (gum bleeding) and acute kidney injury 
were also tolerable (Table 3).
In multivariable analyses of the risk factors for pulmo-
nary manifestation, high parasite counts were the great-
est risk factor for pulmonary oedema (AOR 2.17 [95% CI 
Table 1 General characteristics of  210 vivax malarial 
patients
Variables No. of patients (%)
Age range; years
 15–19 12 (5.7)
 20–29 54 (25.7)
 30–39 43 (20.5)
 40–49 51 (24.3)
 50–59 29 (13.8)
 >60 21 (10.0)
Gender, male/female 154/56 (73.3/26.7)
Number, hospitalisation/ICU 88/11 (41.9/5.2)
Underlying conditions (N = 203)
 Hypertension 18 (8.9)
 Diabetes mellitus 11 (5.4)
 Heart failure 2 (1)
 Malignancy 1 (0.5)
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1.15–4.12], P = 0.017), and low eGFR was a risk factor for 
pulmonary manifestation (AOR 0.98 [95% CI 0.95–0.99], 
P = 0.034) (Additional file 2).
Other complications of vivax malaria
Abdominal CT or ultrasonography was performed on 
72 of the patients. Among them, there were 13 cases of 
hepatomegaly, one case of liver haematoma, 41 cases of 
splenomegaly, ten cases of spleen infarction (including 
two cases previously reported [23]) and one case of sub-
capsular splenic haemorrhage. Two patients presented 
retinal haemorrhage (including one case previously 
reported [24]). There was no co-infection with bacteria 
or fungus in the blood cultures (Table 4).
Discussion
The present study confirmed that in Korea, adult patients 
with vivax malaria primarily show the following charac-
teristics; few previous clinical malaria episode; no asso-
ciation with concurrent bacteraemia; extremely rare 
occurrences of severe anaemia, hypoglycaemia, and 
acute kidney injury complications; and no or low mor-
tality. However, cerebral and pulmonary manifestations, 
spontaneous bleeding, shock, and metabolic acidosis are 
relatively common, as reported previously [11, 12] (see 
Additional file 3). Similar to the two previous reports in 
Korea, no deaths occurred in the present study. One study 
from Europe, investigating imported vivax malaria, also 
reported very no mortalities [10]. In contrast, the stud-
ies in tropical areas, such as India, Indonesia and Pakistan 
reported 0.3–9.0% mortality [6, 25–35] (see Additional 
file 4). Although multiple factors could be responsible for 
the differences in geographic mortality, the most probable 
cause is the ease of access to medical facilities. Almost 
all Korean patients can use the public health insurance 
scheme, which can also decrease the time before admis-
sion. For the patient who received ECMO, without such 
life-supporting equipment, the patient would unlikely 
to have survived. In addition, rare or lack of other co-
infections, which can cause complications associated 
with vivax malaria, such as typhoid fever, brucellosis and 
dengue fever, also contribute to the low mortality. These 
infections are rare or non-existent in Korea. Furthermore, 
previous studies showed that drug-resistant vivax was 
associated with severe malaria [31], whereas chloroquine 
resistance is rarely reported in Korea [18].
The type and relative frequency of severe complica-
tions seem to be different to previous reports from tropi-
cal or subtropical countries. For instance, severe anaemia 
was previously reported to be the most common cause 
of severe malaria in a tropical area [36]. In comparison, 
Table 2 Complications suggestive of severe vivax malaria
Shock: systolic blood pressure < 80 mmHg, Hypoxemia: oxygen 
saturation < 92% on room air, Severe anemia: hemoglobin < 7 g/dL together 
with a parasite count > 10,000/μL, Jaundice:bilirubin > 3 mg/dL together with 
a parasite count > 100,000/μL, Metabolic acidosis: bicarbonate < 15 mmol/L or 
Lactate > 5 mmol/L, Acute renal failure: Cr 3.0 > mg/dL or blood urea > 60 mg/
dL, Hypoglycemia: < 40 mg/dL
Variables, no. of examinations No. of patients (%)
Death, 210 0 (0.0)
Cerebral malaria, 210 5 (2.4)
Spontaneous bleeding, 210 3 (1.4)
Shock, 210 4 (1.9)
Pulmonary manifestation, 183 40 (21.9)
 Radiologically confirmed, 183 40 (21.9)
 Hypoxemia, 127 7 (5.5)
Severe anaemia, 210 0 (0.0)
Jaundice, 207 0 (0.0)
Acute renal failure, 204 2 (1.0)
Hypoglycemia, 206 0 (0.0)
Metabolic acidosis, 86 3 (3.5)
Total severe vivax malaria, 210 44 (21.0)
Table 3 Complications in outpatients, inpatients, ICU, mechanical ventilator and ECMO cases
ICU Intensive Care Unit, ECMO extracorporeal membrane oxygenation, Inpatients general ward + ICU, ICU included mechanical ventilation and ECMO
Variables Outpatients, N = 122 Inpatients, N = 88
Inpatient, N = 88 ICU, N = 11 Ventilator, N = 5 ECMO, N = 1
Cerebral malaria 0 5 4 2 1
Spontaneous bleeding 1 2 0 0 0
Shock 0 4 4 4 1
Pulmonary manifestation 7 33 11 5 1
Severe anaemia 0 0 0 0 0
Severe jaundice 0 0 0 0 0
Acute kidney injury 1 1 1 1 1
Hypoglycemia 0 0 0 0 0
Metabolic acidosis 0 3 3 2 1
Total severe vivax malaria 9 35 11 5 1
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no patients also presenting with severe anaemia were 
found in the present investigation. Falciparum malaria, 
intestinal helminths and nutritional deficiency are com-
pounding factors in severe anaemia [9], whereas these 
factors do not exist or occur very rarely present in Korea. 
Hypoglycaemia or severe jaundice was also absent in 
the present study. Conversely, pulmonary oedema had a 
higher incidence in present study than tropical or sub-
tropical areas [6, 25–35]. Frequent radiologic exams are 
considered an important cause. In the present study, 188 
(87%) patients had a radiologic exam, while 15 patients 
had only pulmonary oedema on chest roentgenogram 
without hypoxaemia (saturated oxygen <95%). Although 
this indicates that more pulmonary oedemas could be 
detected more frequently by routine radiologic examina-
tions, the present study included five cases of mechani-
cal ventilations, which suggests a common occurrence 
of pulmonary complications is possible and is distinct 
from that caused by frequent radiologic examinations. 
In this instance, a low level of immunity, due to no pre-
vious exposure to malaria, is considered to be the main 
cause. Shock and cerebral malaria were also relatively 
common in the present study, while acute kidney injury 
presented with low incidence. It is hypothesised that the 
complications common to the present study might have 
different pathogeneses compared to the uncommon 
complications.
Although there are few studies concerning pulmonary 
oedema of vivax malaria, low eGFR is generally con-
sidered to be a risk factor. Accordingly, in the logistic 
regression model, patients with low eGFR were at risk 
of pulmonary oedema. However, the present study also 
revealed that parasite counts were a risk factor for pul-
monary oedema. Generally, it has been accepted that 
parasitaemia is not associated with the severity of vivax 
malaria [9]. Partial immunity could explain this incon-
sistency. Patients with low pre-existing immunity to vivax 
malaria (such as South Korea) could be more sensitive to 
parasitaemia, resulting in a severe immune reaction that 
could be associated with the severity of the disease or 
pulmonary oedema. In contrast, patients with relatively 
high immunity could be less sensitive to parasitaemia. 
Most previous studies were performed in areas with rela-
tively high immunity, hence, parasitaemia could not seem 
to be associated with the severity of vivax malaria. More 
research is needed to clarify the link between parasitae-
mia and the severity of vivax malaria.
There are limited comparable published papers on 
complications in patients with no or low pre-existing 
immunity to vivax malaria. Yet, in addition to the medi-
cal environment, the extent of malaria endemicity and 
dissimilarities in the criteria of severe complications, a 
lack of specific immunity may contribute to the various 
types of severe complications. In particular, interna-
tional travellers or patients with neurosyphilis receiving 
induced malaria might be such cases, although these 
patients also present certain differences to the present 
cases. Still, a comparison can be made between patients 
who have received malariotherapy for neurosyphilis and 
those in the present study that had not suffered from 
malaria. Malariotherapy has killed as many as 15% of 
the patients who have received it, which indicates the 
severity of induced vivax malaria. However, as above-
mentioned there are several differences between patients 
receiving malariotherapy and those in the present study 
including the presence of underlying disease (neurosyph-
ilis), poor general health in patients with neurosyphilis 
and a relatively higher inoculation dosage in malariother-
apy [37, 38]. Meanwhile, in a survey of 526 patients with 
vivax malaria in Europe, there were no deaths and only a 
few severe clinical complications were reported. A total 
of 312 patients were admitted, 30 patients had complica-
tions and seven patients had clinically significant severe 
disease [10]. Nonetheless, there were several missing data 
in the complications and the classification and definition 
of the complications were not described. And, among 
554 patients with imported vivax malaria, 234 had taken 
prophylactic anti-malarial drugs that may have caused 
fewer complications. In addition, this study includes 
many immigrants and refugees, expatriates and foreign 
visitors. Therefore, it is highly possible that many of them 
are semi-immune to vivax malaria. For the above-men-
tioned reasons, none of these studies represents the exact 
situation of vivax malaria in Korea.
A comparison of the study results from various geo-
graphical areas is complicated by the heterogeneity of 
the patients, such as in- or outpatients, duration of ill-
ness and frequencies of co-morbidity or co-infection. 
The present study attempted to elucidate whether the 
place of management (namely, outpatient, inpatient and 
Table 4 Other complications of vivax malarial patients







 Subcapsular hemorrhage 1
Retinal hemorrhage 2
Elevated muscle enzyme, 29 6
Other bacteraemia, 81 0
Hyperparasitaemia, 207 0
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ICU) could discriminate between severe and mild vivax 
malaria. Accordingly, the numbers of patients with severe 
complications progressively increased from 7.4% (outpa-
tients) to 39.8% (inpatients) to 100% (ICU patients). Thus, 
the ratios of inpatients/total patients and ICU patients/
inpatients might estimate the overall severity of the 
study patients, which, in the present study, were 41.9 and 
12.5%, respectively, and those in Peru were 1.6 and 26.4%, 
respectively. It can be cautiously speculated, therefore, 
that physicians in Peru generally managed mild vivax 
malaria patients (or the actual severity may be milder in 
Peru), whereas vivax malaria in hospitalised patients in 
Peru is more severe (possibly because of more restricted 
hospitalisation). This assumption is compatible with the 
present result that the overall severity of vivax malaria in 
Korea is more severe than that in Peru but mortality is 
lower because of early hospitalisation and subsequently, 
proper medical management.
Various non-severe complications are reported in vivax 
malaria, such as splenic (rupture, infarction, haemor-
rhage) and ophthalmic issues, as well as myocarditis and 
pancreatitis [24, 39–43]. These reports, however, are 
usually case reports or case series. Thus, it is not pos-
sible to elucidate their overall and relative incidences 
in vivax malaria. The present study revealed a relatively 
high incidence of splenic infarction, possibly by frequent 
use of the abdominal CT scan or ultrasonography for 
evaluation of fever. There were no splenic ruptures, and 
all splenic infarctions were resolved after conservative 
management, without splenectomy or other procedures 
required. Four patients with splenic infarction had con-
comitant pulmonary oedema, without any statistically 
significant association between these two conditions. 
Retinal haemorrhage was also relatively common in the 
present study. Retinal haemorrhage is associated with 
visual disturbance and its incidence is not affected by fre-
quent laboratory or radiographic examinations. Its inci-
dence may represent an actual frequency in vivax malaria 
in non-immune patients. In the present study, retinal 
haemorrhage patients did not present any other severe 
complications, although a correlation between retinal 
haemorrhage and the severity of vivax malaria has been 
previously reported [44].
The present research has several limitations. First, our 
study was performed in a single centre. The generaliza-
tion of our research as a representation of all temperate 
regions can be dangerous. Second, it was a retrospective 
study. However, many variables were inspected, includ-
ing variables that have not yet been studied. Lastly, the 
present study did not included pregnant women and chil-
dren, which results in very rare occurrence of malaria in 
children and expectant mothers.
Conclusions
Vivax malaria in Korea can be life-threatening. However, 
there were no fatalities due to adequate medical man-
agement. The types of severe complications of P. vivax 
infections reported in this study may be different from 
previous studies, hence, additional studies are needed to 
reveal the underlying cause for these differences.
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